External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Polycythemia Vera

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Dec 7 / Roche and Genentech
Molecular Response Patterns in Hydroxyurea (HU)-Resistant or -Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study
This poster reports results from an exploratory analysis assessing the baseline mutational profile and JAK2 V617F variant allele frequency of patients with hydroxyurea-resistant or -intolerant polycythemia vera treated with idasanutlin in an international Phase II study.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 6 / Roche and Genentech
Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
This oral presentation reports safety and efficacy results from an international Phase II study of idasanutlin in patients with hydroxyurea-resistant or -intolerant polycythemia vera.

Ask a question or share feedback